1. ILD diagnosis is usually multidisciplinary
Thoraxklinik Heidelberg describes ILD diagnosis as requiring interdisciplinary expertise, with pulmonology, radiology and pathology findings discussed together in an ILD board. Charité also runs a dedicated outpatient clinic for rare and interstitial lung diseases including pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis and autoimmune-associated lung disease.
2. Bring the original CT images, not only the report
Thoraxklinik specifically asks new ILD patients to bring previous CT imaging. For an international second opinion, the image files can be as important as the written report because radiologic pattern recognition may influence whether biopsy or other testing is necessary.
- High-resolution chest CT images and reports
- Current and previous pulmonary-function tests
- Oxygen saturation and exercise-test results when available
- Autoimmune and exposure history
- Bronchoscopy or biopsy reports if previously performed
- Current medicines and prior antifibrotic or immunosuppressive treatment
3. The exact ILD subtype changes treatment
ILD can include idiopathic pulmonary fibrosis, other idiopathic interstitial pneumonias, autoimmune-related lung disease, hypersensitivity pneumonitis, sarcoidosis and many rarer conditions. Treatment may differ substantially between these diagnoses, so a second opinion should first clarify classification and evidence for progression.
4. Bronchoscopy or biopsy is not automatically required
Charité and Thoraxklinik both list bronchoscopy among available diagnostic tools, but whether bronchoalveolar lavage, cryobiopsy or another tissue procedure is useful depends on the radiologic and clinical question. Ask what uncertainty the invasive procedure is expected to resolve.
5. Advanced disease may require oxygen, rehabilitation or transplant-center discussion
Progressive fibrotic lung disease can eventually require long-term oxygen, rehabilitation and, for selected patients, transplant-center assessment. Lung transplantation is a separate regulated clinical pathway and should not be presented as a routine medical-tourism service.
Official and primary sources
Sources last checked 2026-09-21.